普遍Lynch筛查时代错配修复缺陷子宫内膜癌的临床病理特征与结局
该回顾性队列研究纳入2012-2016年1018例子宫内膜癌手术患者,所有肿瘤行错配修复免疫组化及MLH1启动子甲基化检测。结果显示71.6%为MMR-I、23.8%为MMR-DM、4.6%为MMR-DU,三组总体PFS和OS无差异,但子宫内膜样癌中MMR-DM与更差PFS相关(HR 2.51),早期患者同样显著。
要点
- 子宫内膜癌中MMR-DM占23.8%,MMR-DU占4.6%,MMR-I占71.6%。
- 早期(I/II期)子宫内膜样癌中该风险持续存在(HR 2.66)。
核心结论
- MMR缺陷与不良预后因素相关,在子宫内膜样癌尤其早期患者中与更差PFS相关。
- 在Lynch筛查之外进行MMR检测具有预后价值,值得考虑作为生物标志物纳入前瞻性临床试验。
研究设计与样本
- 回顾性队列研究,使用前瞻性维护的妇科肿瘤登记库,纳入2012至2016年接受手术的子宫内膜癌患者共1018例。
- 所有病理标本行错配修复免疫组化检测,并反射性行MLH1启动子甲基化检测。
主要发现
- 总体71.6%为MMR-I,23.8%为MMR-DM,4.6%为MMR-DU。
- 与MMR-DU相比,MMR-DM肿瘤与更老年龄、绝经后状态、淋巴血管间隙浸润和纯子宫内膜样组织学相关。
- 多因素分析中,与MMR-I相比,MMR-DM肿瘤与更老年龄、子宫内膜样组织学、淋巴血管间隙浸润和更高分级相关。
- 三组总体PFS和OS无差异。
关键数值与推荐
- MMR-I:错配修复表达完整;MMR-DM:因MLH1甲基化导致错配修复缺陷;MMR-DU:错配修复缺陷但无MLH1甲基化。
临床怎么用
- 对子宫内膜癌患者行MMR免疫组化及MLH1甲基化检测,不仅用于Lynch筛查,还可提供预后信息。
- 早期子宫内膜样癌中若为MMR-DM,应关注更差PFS风险,考虑更密切随访或临床试验。
局限性
- 回顾性设计,可能存在选择偏倚。
- 单中心登记库数据,外推性需验证。
- 未报告具体治疗细节及多因素模型中其他混杂因素调整情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate clinicopathologic characteristics and survival impact associated with mismatch repair (MMR) deficient subgroups of endometrial cancer (EC) in patients undergoing universal screening for Lynch Syndrome. METHODS: A retrospective cohort study using a prospectively maintained gynecologic oncology registry of patients who underwent surgery for EC was conducted. All pathology specimens underwent tumor testing using immunohistochemistry for MMR deficiency with reflex MLH1 promotor methylation testing. Tumors were classified as MMR-I (intact MMR expression), MMR-DM (MMR deficient due to MLH1 methylation), and MMR-DU (MMR deficient without MLH1 methylation). Univariate and multivariate analysis performed to determine factors associated with MMR-DM. Progression-free survival (PFS) and overall survival (OS) analyzed by stage and endometrioid subgroup. RESULTS: From 2012 to 2016, 1018 EC patients were identified and screened. Overall, 71.6% were classified as MMR-I, 23.8% MMR-DM, and 4.6% MMR-DU. In comparison to MMR-DU, MMR-DM tumors were associated with older age, postmenopausal status, lymphovascular space invasion, and pure endometrioid histology. Compared to MMR-I, MMR-DM tumors were associated with older age, endometrioid histology, lymphovascular space invasion, and higher grade on multivariable analysis. There was no difference in PFS and OS between the three groups overall. In patients with endometrioid EC, MMR-DM tumors were associated with lower PFS vs. MMR-I (HR:2.51, CI:1.54, 4.10, P < 0.001). This effect persisted for stage I/II endometrioid EC (HR 2.66, CI:1.34, 5.26 p = 0.005). No difference in PFS or OS was noted among stage III/IV endometrioid tumors. CONCLUSION: MMR deficiency is associated with adverse prognostic factors and worse PFS among endometrioid tumors, particularly in early stage EC. MMR testing outside of LS screening has prognostic value, warranting consideration for inclusion as a biomarker in prospective clinical trials.
引用
- Carr C, Son J, Yao M, et al. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening. Gynecol Oncol. 2020. PMID: 33046272. doi:10.1016/j.ygyno.2020.09.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。